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BACKGROUND AND PURPOSE
Statins are amongst the most widely prescribed drugs for those at risk of cardiovascular disease, lowering cholesterol levels by
inhibiting 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase. Although effective at preventing cardiovascular disease, statin use
is associated with muscle weakness, myopathies and, occasionally, fatal rhabdomyolysis. As simvastatin, a commonly prescribed
statin, promotes Ca2+ release from sarcoplasmic reticulum (SR) vesicles, we investigated if simvastatin directly activates skeletal
(RyR1) and cardiac (RyR2) ryanodine receptors.
EXPERIMENTAL APPROACH
RyR1 and RyR2 single-channel behaviour was investigated after incorporation of sheep cardiac or mouse skeletal SR into planar
phospholipid bilayers under voltage-clamp conditions. LC-MS was used to monitor the kinetics of interconversion of simvastatin
between hydroxy-acid and lactone forms during these experiments. Cardiac and skeletal myocytes were permeabilised to
examine simvastatin modulation of SR Ca2+ release.
KEY RESULTS
Hydroxy acid simvastatin (active at HMG-CoA reductase) signiﬁcantly and reversibly increased RyR1 open probability (Po) and
shifted the distribution of Ca2+ spark frequency towards higher values in skeletal ﬁbres. In contrast, simvastatin reduced RyR2 Po
and shifted the distribution of spark frequency towards lower values in ventricular cardiomyocytes. The lactone pro-drug form of
simvastatin (inactive at HMG-CoA reductase) also activated RyR1, suggesting that the HMG-CoA inhibitor pharmacophore was
not responsible for RyR1 activation.
CONCLUSION AND IMPLICATIONS
Simvastatin interacts with RyR1 to increase SR Ca2+ release and thus may contribute to its reported adverse effects on skeletal
muscle. The ability of low concentrations of simvastatin to reduce RyR2 Po may also protect against Ca2+-dependent arrhythmias
and sudden cardiac death.
Abbreviations
AF, atrial ﬁbrillation; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; CCD, central core disease; FDB, ﬂexor
digitorum brevis; HMG-CoA, 3-hydroxy-3-methylglutaryl CoA; Log D, partition coefﬁcient; MH, malignant hyperthermia;
Po, open probability; RyR, ryanodine receptor; Sim-H, simvastatin hydroxy acid; Sim-L, simvastatin lactone; SR, sarco-
plasmic reticulum; Trans, luminal
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Introduction
Statins are competitive inhibitors of 3-hydroxy-3-meth-
ylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting
enzyme in the synthesis of cholesterol. They are the most
widely prescribed medication for the treatment of hyper-
cholesterolaemia and prevention of cardiovascular disease.
Furthermore, statin use is increasing with recent reductions
in the cardiovascular risk threshold for statin prescription
(NICE, 2014). The efﬁcacy of statin drugs has been demon-
strated in many large clinical trials (Collins et al., 2016),
and while their success has been unrivalled, they are also
associated with causing a variety of muscle-related com-
plaints (Bruckert et al., 2005; Buettner et al., 2012; Stroes
et al., 2015). Patients prescribed statin treatment often re-
port muscle pain and weakness, and in serious cases, fatal
rhabdomyolysis can occur (Hodel, 2002). Observational
studies have suggested that between 10 and 15% of pa-
tients undergoing statin therapy experience these side ef-
fects, and this has restricted their use in certain contexts.
As a result many patients have so far been unable to bene-
ﬁt from statins protection against cardiovascular disease, as
well as their pleiotropic cardioprotective effects (Thompson
et al., 2003).
All statins are reported to cause muscle-related side ef-
fects; however, the occurrence of these adverse effects is
not correlated with potency of HMG-CoA reductase inhibi-
tion but does appear to become more severe with increas-
ing doses (Armitage, 2007). The mechanisms underlying
this toxicity have not yet been fully elucidated although
there are several suggested off-target mechanisms such as
inhibition of mitochondrial respiration (Schirris et al.,
2015) and induction of apoptosis (Johnson et al., 2004;
Borahay et al., 2014). It has also been reported that certain
statins can stimulate the release of Ca2+ from isolated sar-
coplasmic reticulum (SR) vesicles (Inoue et al., 2003) and
from the SR in muscle ﬁbres (Sirvent et al., 2005a; Sirvent
et al., 2005b). It is therefore possible that statins directly
affect the function of the ryanodine receptor RyR1, the
predominant SR Ca2+ release channel in skeletal muscle.
Mutations to RyR1 result in a range of serious skeletal
muscle diseases including congenital myopathies such as
malignant hyperthermia (MH), central core disease (CCD)
and exercise-induced rhabdomyolysis (Sambuughin et al.,
2005; Chelu et al., 2006). In MH and CCD, muscle
weakness and hyperthermia are associated with RyR1
channels that display an enhanced sensitivity to agonists
(Chelu et al., 2006). Interestingly, recent population stud-
ies have reported a link between statin-induced myopathy
and patients with RyR1 mutations that give rise to MH
(Zutt et al., 2014; Hedenmalm et al., 2015). In addition,
it has been shown that mice carrying the MH-linked
mutation, Y524S, are more sensitive to simvastatin than
wild-type animals, demonstrating increased SR Ca2+ leak
from ﬂexor digitorum brevis (FDB) ﬁbres, as well as in-
creased heat production and muscle contractures
(Knoblauch et al., 2013).
In view of the known association of ‘leaky’ RyR1 channels
with severe muscle myopathies, we therefore investigated if
simvastatin exerts a direct effect on the gating and
conducting properties of the native skeletal RyR1 channel
complex incorporated into planar phospholipid bilayers
under voltage-clamp conditions. We also examined if
simvastatin could alter the spontaneous SR Ca2+ release from
RyR clusters (Ca2+ sparks) in situ in single isolated, permeabilised
rat skeletal muscle cells.
There are three mammalian isoforms of RyR. RyR1 is
found predominately in skeletal muscle, RyR2 in cardiac
muscle and RyR3 is widely expressed in various tissues but of-
ten at low levels (Zucchi and Ronca-Testoni, 1997). Although
a few agents have been suggested to speciﬁcally interact with
only one of these mammalian isoforms, a ligand that modu-
lates the function of one RyR isoform will usually interact
with other isoforms even if the response is subtly different
(Venturi et al., 2014). Therefore, since statins are given to pa-
tients with a history of heart disease and an increased likeli-
hood of experiencing arrhythmias, it is important to
investigate whether statins also affect cardiac RyR2 channel
function. Altering the single-channel conductance or open
probability (Po) of RyR2 might inﬂuence the release of SR
Ca2+ thereby potentially affecting contractility and the
propensity for Ca2+-dependent arrhythmias. Consequently,
we have also investigated whether simvastatin alters the
single channel behaviour of RyR2 incorporated into bilayers
and Ca2+ sparks in isolated, permeabilised ventricular
cardiomyocytes.
Simvastatin is one of the most commonly prescribed
statins. While there are a variety of structurally distinct statin
molecules, all have in common a modiﬁed hydroxyglutaric
acid unit which is responsible for inhibition of HMG-CoA re-
ductase (Istvan and Deisenhofer, 2001). This unit may exist as
either a lipophilic lactone ring (to give the closed form of
simvastatin lactone, Sim-L) or an open form as a more
hydrophilic free acid (simvastatin hydroxy acid, Sim-H).
Simvastatin is prescribed in its lactone form, which is
subsequently converted in vivo to the open active form
(Figure 1A) (Kearney et al., 1993). This lipophilicity (log D at
pH 7.4) (McKenney, 2003) is also correlated with the relative
occurrence of muscle-related side effects; cerivastatin (log
D ~ 1.75), which was withdrawn from the market in 2001, is
also the most lipophilic statin that has been used clinically
(White, 2002). More lipophilic drugs typically display greater
levels of passive diffusion across cellular membranes, thus af-
fecting the distribution of the drug. For example, simvastatin
(log D ~ 1.60 in Sim-L form) can easily cross the blood–brain
barrier, while the structurally similar but more hydrophilic
pravastatin (log D ~ 0.84 in lactone form) does not
(Hamelin and Turgeon, 1998; McKenney, 2003).
Our results show RyR isoform-speciﬁc effects of simva-
statin. We demonstrated that ≥1 μM Sim-H signiﬁcantly
increases the Po of RyR1 in a cytosolic Ca2+-dependent
manner. In line with these experiments, statin treatment
tends to increase the frequency of Ca2+ sparks in
permeabilised skeletal muscle cells. In contrast, low concen-
trations of Sim-H (1 μM) reduced the Po of RyR2. Sim-H also
tended to reduce the frequency of Ca2+ sparks in isolated
permeabilised ventricular cardiomyocytes. It will be
important to investigate the effects of other prescribed statins
on cardiac and skeletal RyR channel function as the effects
described in this paper may contribute to the unwanted
muscular side effects or to, as yet, uncharacterized effects on
cardiac function.
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Methods
Animals and ethical approval
Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).
Mouse skeletal muscle was used for RyR1 single-channel ex-
periments and [3H]-ryanodine binding; sheephearts were used
for RyR2 single-channel experiments and [3H]-ryanodine
binding; rat skeletal ﬁbres and cardiac myocytes were used
for analysis of Ca2+ sparks in permeabilised cells. All rodent
work was carried out in accordance with the Directive
2010/63/EU of the European Parliament with local approval
of the Animal Research Committee according to the regula-
tions on animal experimentation at the University of Oxford
(mouse) and the Animal Welfare and Ethical Review board at
the University of Leeds (rat). Rats were housed in a conven-
tional unit, in ﬁlter top cages with Aspen bedding on a 12 h
light/dark cycle with free access to food and water. Mice were
housed in a speciﬁc pathogen free unit in individually venti-
lated cage on a 12 h light/dark cycle with free access to food
and water. Sheep hearts were obtained from an abattoir. To
comply with the ‘three Rs’ principles, we prepared SR mem-
branes from animals that were killed for other purposes
wherever possible (sheep hearts, mouse skeletal muscle). Our
choice of tissue was based on the similarity of RyR proteins be-
tween species and designed to minimize animal use without
compromising the integrity of the data. Identity between
mouse (E9PZQ0.1) and rat (F1LMY4.1) RyR1 sequences is
96%. RyR2 sequences are also 96% identical between sheep
(XP_014959831.1) and rat (B0LPN4).
Single-channel recordings
Heavy sarcoplasmic reticulum (HSR) membrane vesicles were
prepared from mouse skeletal muscle or sheep hearts as de-
scribed previously (Sitsapesan and Williams, 1990). Mice
(C57BL/6) were 10–14 weeks old, of either sex. Sheep (Suffolk
breed) were 8–10 months old, of either sex.
RyR1 or RyR2 channels were incorporated into planar
phospholipid bilayers as previously described (Sitsapesan
et al., 1991), and current ﬂuctuations through RyR channels
were recorded under voltage-clamp conditions with
250 mM HEPES, 80 mM Tris, 10 μM free Ca2+, pH 7.2, on
the cytoplasmic side and 250 mM glutamic acid, 10 mM
HEPES, pH to 7.2 with Ca(OH)2 (free [Ca
2+] approximately
50 mM) on the trans (luminal) side of the bilayer at 21°C.
The trans chamber was voltage-clamped at ground. The
Figure 1
The effects of cytosolic Sim-H on RyR1 channel gating. (A) The chemical structures of Sim-L and Sim-H. The interconversion between lactone and
hydroxy acid forms shows a strong dependence on pH. (B) Representative mouse skeletal RyR1 single-channel current ﬂuctuations in the presence
of 10 μM cytosolic Ca2+ alone (top trace), after cytosolic addition of 1 and 10 μMSim-H (as indicated) and after wash-out of Sim-H back to control
conditions (10 μM cytosolic Ca2+, bottom trace). The Po above each trace refers to the value determined over 3 min. O and C indicate the open
and closed channel levels respectively. (C) Mean RyR1 Po values with 10 μM cytosolic Ca2+ as sole channel activator and after addition of 1 μM
Sim-H, 10 μM Sim-H and wash-out of Sim-H. Mean and SEM are shown; numbers on the bars indicate number of independent experiments
[n = 14 (10 μM Ca2+, 1 μM and 10 μM Sim-H), n = 7 (washout); *P < 0.05].
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compound to be investigated was added to the cytosolic
chamber. The free [Ca2+] and pH of the solutions were main-
tained constant during the experiment and were determined
using a Ca2+ electrode (Orion 93-20, Thermo Fisher Scientiﬁc,
UK) and a Ross-type pH electrode (Orion 81-55, Thermo
Fisher Scientiﬁc, UK) as previously described (Sitsapesan
et al., 1991). Sub-activating cytosolic Ca2+ levels were ob-
tained by addition of 1 mM EGTA to the cytosolic chamber
and the approximate free [Ca2+] calculated using the
MaxChelator programme (http://maxchelator.stanford.edu).
The addition of Sim-H or Sim-L did not alter the free [Ca2+]
or pH of solutions.
Single-channel analysis
Single-channel recordings were digitized at 20 kHz and low-
pass ﬁltered at 800 Hz. Po was determined over 3 min of con-
tinuous recording at 0 mV using 50% threshold analysis
(Colquhoun and Sigworth, 1995) in Clampﬁt 10.6 (Molecular
Devices, USA) as previously described (Sitsapesan and
Williams, 1990; Sitsapesan et al., 1991). Where Po values are
shown in ﬁgures, the Po above each trace refers to the value
determined over 3 min for that particular channel. Where
more than one channel was incorporated into the bilayer,
Po is reported as an average (total Po divided by number of
channels). Lifetime distributions were constructed using
Clampﬁt 10.6 (Molecular Devices, USA) and ﬁtted to a proba-
bility density function by the method of maximum likeli-
hood (Colquhoun and Sigworth, 1995) according to the
following equation:
f tð Þ ¼ ∑
N
i
aif 0 t  lnτið Þ
where i is the number of exponential components of the dis-
tribution, τi are the time constants and ai are the fractions of
the total events represented by the ith component. The set
of parameters were adjusted by the maximum likelihood iter-
ative algorithm until the optimum value of the log of likeli-
hood L was reached (Blatz and Magleby, 1986).
[3H]-ryanodine binding
The binding of [3H]-ryanodine to RyR was measured as previ-
ously described (Sigalas et al., 2009). In brief, mouse skeletal
mixed membrane vesicles containing 500 μg protein·mL1,
or sheep cardiac SR vesicles containing 130 μg protein·mL1
were incubated at 37°C for 90 min with constant shaking in
buffer consisting of 250 mM HEPES, 80 mM Tris, 10 μM free
Ca2+, pH 7.2 in the presence of 5 nM [3H]-ryanodine. Nonspe-
ciﬁc binding was determined in the presence of 1000-fold ex-
cess unlabelled ryanodine. The bound and free ligand were
separated by rapid ﬁltration through Whatman GF/B glass
microﬁbre ﬁlters. The [3H]-ryanodine retained in the ﬁlters
was quantiﬁed by liquid scintillation spectrometry using a
scintillation counter.
Cellular Ca2+- release
Collagenase-digested ﬂexor digitorum brevis (FDB) ﬁbres
(Pickering et al., 2009) and ventricular myocytes (Calaghan
et al., 1998) isolated from male 4–6 week old Wistar rats
(100–150 g) were used for confocal microscopy. FDB ﬁbres
were permeabilised by 2 min exposure to 0.005% saponin
and bathed in intracellular solution containing (mM):
K2SO4 95, HEPES 10, EGTA 0.47, MgCl2 6, Na2-ATP 5, Na2-
creatine phosphate 10, glucose 10, CaCl2 0.13, pH 7.2. Ven-
tricular myocytes were permeabilised by 10 min exposure to
0.001% saponin and bathed in intracellular solution contain-
ing (mM): KCl 100, HEPES 25, EGTA 0.35, MgCl2 5.72,
Na2ATP 5, Na2-creatine phosphate 10, CaCl2 0.05, pH 7.
Permeabilised FDB ﬁbres and ventricular myocytes were
loaded with Fluo-3 pentapotassium salt (25 or 10 μM respec-
tively) and perfused with 10 μM Sim-H for 5 min. Confocal
images were acquired with a Nikon Eclipse TE300 inverted
microscope equipped with a confocal scanhead, Bio-Rad
MicroRadiance 2000 and a ×60 water-immersion objective.
Fluo-3 pentapotassium was excited with the 488 nm line of
a 20 mW coherent sapphire laser, and the ﬂuorescence emit-
ted was measured at >515 nm. Images were acquired in line
scan mode (every 6 ms). Ca2+ sparks were identiﬁed and
analysed with ImageJ software (NIH) using the Sparkmaster
plugin (Picht et al., 2007). Events with a full width at half
maximum <1 μm were ﬁltered from the data.
LC-MS analysis
Sim-H and Sim-L were prepared as 10 mM solutions in water
and DMSO, respectively, and stored at 78°C, and warmed
to room temperature immediately prior to injection; 1 μL of
each solution was added to 1 mL of water or Tris/HEPES
(250 mMHEPES, 80 mM Tris, 10 μM free Ca2+, pH 7.2) buffer,
respectively, and sampling by LC-MS was begun immediately.
Samples were kept at room temperature for the duration of
the analysis. Analyses were performed using a Thermo
Exactive mass spectrometer equipped with Waters Acquity
liquid chromatography system. Instrument control was per-
formed using Thermo Xcalibur Software. Electrospray source
conditions were adjusted to maximize sensitivity; 3 μL of
each sample was injected onto the system. The column was
a 2.1 × 50 mm (3 μm) ACE equivalence C18. A mixed eluent
gradient was employed and is described in Supporting
Information Table S3. The four sample types were analysed
sequentially; the 5 min analysis time for each sample pro-
vided a 20 min sampling frequency for each sample. Mass
analysis was performed using MestReNova MS software
(2016, V11.0), where the peaks were integrated to determine
relative percentages of Sim-L and Sim-H over time.
Statistical analysis
The data and statistical analysis comply with the recommenda-
tions on experimental design and analysis in pharmacology
(Curtis et al., 2015) and were carried out using GraphPad Prism
7.Normalitywas checked using theD’agostino and Pearson test.
Where n ≥ 5, normally distributed data are expressed as mean ±-
SEM and statistical comparisons were made using Student’s t-
test. Where multiple treatments were compared, ANOVA
followedby amodiﬁed t-test was used to assess the difference be-
tween treatments (Galfre et al., 2012). Data that were not nor-
mally distributed are expressed as median + interquartile
range; statistical comparisons were made using the
Mann–Whitney test. A P value of<0.05was taken as signiﬁcant.
Variations in n numbers for single-channel experiments were
due to bilayers breaking during the course of the experiment,
which precluded furthermeasurements being taken. In all cases,
where skeletal and cardiac SRwas used, data were obtained from
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at least ﬁve different membrane preparations prepared from ﬁve
or more animals. For permeabilised skeletal and cardiac cell ex-
periments, spark parameters were obtained from ≥66 cells from
ﬁve rats.
Materials
Simvastatin sodium salt (Sim-H) was purchased from
CalBioTech (567021). Simvastatin lactone (Sim-L) was pur-
chased from Sigma-Aldrich (Dorset, UK). All other chemicals
were purchased from Sigma-Aldrich (Dorset, UK) or VWR
(Poole, UK) unless stated otherwise. Water was deionized
(Millipore, Harrow, UK), and all solutions used in single-
channel experiments were ﬁltered through a membrane with
a 0.45 μm diameter pore (Millipore, Harrow, UK).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Harding et al., 2018), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY
2017/18 (Alexander et al., 2017a,b).
Results
Simvastatin directly modulates RyR1 and RyR2
channel function
The effects of the hydroxy acid form of simvastatin (Sim-H; see
Figure 1A) on native skeletal RyR1 and cardiac RyR2 channel
function were investigated ﬁrst as this is the form which binds
to HMG-CoA reductase. In the presence of 10 μM cytosolic-free
Ca2+, cytosolic addition of Sim-H caused a concentration-
dependent increase in the Po of RyR1 (Figure 1B, C). The in-
crease in RyR1 Po was readily reversed to control values after
washout of the cytosolic chamber. Sim-H did not affect single-
channel conductance (Figure 2A) under these conditions nor
were signiﬁcant changes in channel Po observed when Sim-H
was added to the luminal side of the bilayer (Figure 2B). Very
high concentrations of simvastatin were not used in single-
channel experiments because statins are lipophilic agents that
would be expected to destabilize artiﬁcial bilayers. To demon-
strate that the effects of simvastatin are not artefacts of the arti-
ﬁcial bilayer membrane, the binding of [3H]-ryanodine to
isolated skeletal SR vesicles was also assessed. Ryanodine only
binds to open RyR channels, thus providing an index of Po for
populations of RyR in their native membranes. This is an
Figure 2
The effects of Sim-H on RyR1 channel function. (A) Single-channel current–voltage relationship for RyR1 before and after simvastatin treatment.
(B) Mean RyR1 Po values before and after addition of 10 μM Sim-H to the luminal (trans) side of the bilayer (mean and SEM are shown; n = 6).
(C) Stimulation of [3H]-ryanodine binding to mouse skeletal muscle SR membrane vesicles by 10 μM cytosolic Ca2+ alone (control), and in the
additional presence of Sim-H (at indicated concentrations) or caffeine (10 mM) (mean and SEM; n = 5; *P < 0.05).
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approximate Po assay because it depends on ryanodine binding
to RyR, and the conditions of the binding assay can never be ex-
actly equivalent to those of a single-channel experiment. Sim-H
stimulated the binding of [3H]-ryanodine at μM concentrations
(10–300 μM).
Figure 2C compares the effect of an optimal concentration
of caffeine suggesting that Sim-H is more potent and more
effective as an activator of RyR1 than caffeine (Figure 2C).
Where only one channel had incorporated into the bi-
layer, we performed lifetime analysis to examine the mech-
anism of the statin-induced increase in Po. Figure 3A
shows that there was a small increase in the mean open
time but a 20-fold reduction in the mean closed time.
Detailed analysis of the open and closed lifetime distribu-
tions (see typical example in Figure 3B and see Supporting
Information Table S1 for τ values and percentage areas of
replicates) identiﬁed additional longer open states and
demonstrated that all closed lifetime constants were mark-
edly shortened. Thus, although Sim-H caused a small in-
crease in open dwell times, the major mechanism for the
increase in RyR1 Po was an increase in frequency of chan-
nel opening.
Figure 3
Effects of cytosolic Sim-H on lifetime distributions. (A) The effect of Sim-H on mean open and closed times (*P < 0.05; mean and SEM, n = 5).
(B) Open and closed lifetime distributions and probability density functions for a representative RyR1 channel activated solely by 10 μM
cytosolic Ca2+ (top), and after addition of Sim-H (bottom). The τ values (time constants) and percentage areas are shown.
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To further investigate the mechanisms underlying Sim-H
activation of RyR1, we lowered the free cytosolic [Ca2+] to
sub-activating levels (~1 nM) after channel activation by
10 μM Sim-H. A typical experiment is shown in Figure 4A.
In the presence of activating [Ca2+], the response to 10 μM
Sim-H can be observed. Subsequent lowering of the cytosolic
[Ca2+] to sub-activating concentrations (~1 nM; third trace)
completely abolished any channel openings (Po = 0). Thus,
Figure 4
Ca2+-dependent and -independent actions of Sim-H on RyR1 channel gating. (A) Representative RyR1 channel recordings in the presence of
10 μM cytosolic Ca2+ (top trace), and after sequential additions of 10 μM cytosolic Sim-H (second trace), and 1 mM EGTA (free cytosolic
[Ca2+] ~1 nM) (bottom trace). The Po above each trace refers to the value determined over 3 min. O and C indicate the open and closed channel
levels respectively. (B) Mean data and SEM from six independent experiments similar to the one shown in (A); n = 6; *P< 0.05. (C) Representative
RyR1 single-channel behaviour in the presence of subactivating cytosolic Ca2+ (free [Ca2+] ~1 nM) (top trace) to show zero openings. There are still
no (zero) openings after addition of 10 μM Sim-H (second trace). The lower traces provide examples of the longer type of openings elicited after
addition of 50 μM Sim-H. O and C indicate the open and closed channel levels respectively. The symbol (*) highlights long channel openings typ-
ical of Ca2+-independent RyR openings (the nature of these openings has been described previously; Sitsapesan and Williams, 1990, Kermode
et al., 1998). (D) Open lifetime distributions and probability density function for a representative RyR1 channel activated solely by 50 μM Sim-
H in the absence of activating cytosolic Ca2+ [~1 nM].
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the 10 μM Sim-H is absolutely dependent on the presence of
activating levels of cytosolic Ca2+ in order to raise RyR1 Po.
The mean data are shown in Figure 4B. Since cytosolic Ca2+
(like Sim-H) also activates RyR1 predominantly by increasing
frequency of opening (Smith et al., 1986), it appears that Sim-
H (at low concentrations) is sensitizing the channel to cyto-
solic Ca2+. However, channel openings can be induced in a
Ca2+-independent manner if the concentration of Sim-H is
increased. In Figure 4C, inspection of the trace shows the
longer type of openings that are characteristic of the RyR
Ca2+-independent type openings that have previously been
described for ligands such as caffeine and ATP (Sitsapesan
and Williams, 1990; Kermode et al., 1998). Figure 4D con-
ﬁrms the effect on open times (see also supporting informa-
tion Table S2). Hence, Sim-H can activate RyR1 by
sensitizing the channel to cytosolic Ca2+ at low concentra-
tions, but higher concentrations can activate the channel in
a Ca2+-independent manner.
To investigate the possible site of interaction of the simva-
statin molecule with RyR1, we examined the effect of the
‘HMG-CoA inactive’ lactone form (Sim-L) on RyR1 channel
gating. Sim-L also signiﬁcantly activated RyR1 channels
(Figure 5A, B), suggesting that the region crucial for binding
to and inhibiting the HMG-CoA reductase is different from
the region that is most important for interacting with and
modulating RyR1 activity.
It has been reported previously that the interconversion
of statins has a strong pH dependence (Taha et al., 2016), so
to conﬁrm that the lactone form (Sim-L) does not undergo
hydrolysis during the time frame of our single-channel exper-
iments, we measured the interconversion rate of the lactone
form (Sim-L) into the open ring form of simvastatin (Sim-H)
using LC-MS (Figure 5C). We did the same for Sim-H
(Figure 5D). Sim-L and Sim-H were each dissolved in the
buffer used for the single-channel experiments (Tris/HEPES).
In the case of Sim-L, we found that even after 1 h, 95% of
the simvastatin detected was still in the closed-ring lactone
form. Hence, in the experiment shown in Figure 5A, at least
99% of Sim-L would remain by the end of the experiment.
For Sim-H, there was no apparent tendency for free acid to
undergo ring-closing to form Sim-L, as no detectable levels
of Sim-L were found even after 1 h incubation (Figure 5D).
Since most ligands that interact with RyR1 also bind to
RyR2, we investigated the effects of Sim-H on the the sin-
gle channel behaviour of sheep cardiac RyR2. Unexpect-
edly, we found that 1 μM Sim-H (a concentration that
activated RyR1) signiﬁcantly decreased Po while 10 μM pro-
duced no observable effect (Figure 6A, B). The main reason
Figure 5
The effects of Sim-L on RyR1 channel gating. (A) A representative RyR1 channel recording in the presence of 10 μMcytosolic Ca2+ alone (top trace)
and after addition of 10 μM cytosolic Sim-L (bottom trace) is shown. The Po above each trace refers to the value determined over 3 min. O and C
indicate the open and closed channel levels respectively. (B) Mean RyR1 Po values in the presence of 10 μMCa2+ alone and after addition of 1 μM
Sim-L and 10 μM Sim-L (mean and SEM; n = 6; * P < 0.05). (C) and (D) show interconversion of Sim-L and Sim-H in the buffer used for the single-
channel experiments (Tris/HEPES) over time (mean of three independent experiments). The conversion of Sim-L to Sim-H is <2% over the time
course of the single channel experiment (<20 min).
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for the reduction in Po was the decreased frequency of
channel opening evidenced by the large increase in mean
closed times with no signiﬁcant change to mean open
times (Figure 6C). Interestingly, at higher concentrations
(10 μM), the inhibition in Po was reversed suggesting that
there may be two sites of interaction: a high afﬁnity
inhibition site and a lower afﬁnity activation site. In line
with the single-channel data, we found that [3H]-ryanodine
binding to sheep cardiac heavy SR membrane vesicles was
inhibited by low concentrations of Sim-H (0.5 μM) and
that this effect was reversed for concentrations ≥10 μM
(Figure 6D).
Figure 6
The effects of Sim-H on sheep cardiac RyR2 function. (A) A typical recording of RyR2 in the presence of 10 μM cytosolic Ca2+ (top two traces) and
after addition of 1 μM Sim-H (bottom two traces) is shown. The Po above each trace refers to the value determined over 3 min. O and C indicate
the open and closed channel levels respectively. (B) Mean and SEM RyR2 Po values in the presence of 10 μM cytosolic Ca2+ as the sole channel
activator and in the added presence of increasing concentrations of Sim-H (n = 7; *P < 0.05). (C) The effects of Sim-H on RyR2 mean open and
closed lifetimes. Results are presented as mean and SEM, n = 7. *P < 0.05 before and after addition of 1 μM Sim-H respectively. (D) Stimulation
of [3H]-ryanodine binding to sheep cardiac heavy SR membrane vesicles by Sim-H (at indicated concentrations) or caffeine (10 mM) (mean
and SEM; n = 7; *P < 0.05).
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Acute simvastatin perfusion alters Ca2+ spark
characteristics in cardiac and skeletal myocytes
Next, we wanted to investigate whether effects of Sim-H on
RyR1 and RyR2 would be replicated in a more physiological
setting. Skeletal muscle ﬁbres and ventricular myocytes from
the rat were permeabilised by saponin (to allow free access of
drug to the SR membrane) and perfused acutely with 10 μM
Sim-H for 5 min. Ca2+ sparks, spontaneous releases of Ca2+
from a cluster of RyR channels, were measured in confocal
linescan mode. Sim-H appeared to exert opposing effects on
Ca2+ spark frequency in skeletal ﬁbres and cardiac myocytes.
Representative linescan images illustrate typical Ca2+ spark
frequency observed in skeletal ﬁbres (Figure 7A) and cardiac
myocytes (Figure 7D) in the absence and presence of Sim-H.
The shift towards higher Ca2+ spark frequency in FDB ﬁbres
treated with Sim-H can be visualized in Ca2+ spark frequency
distribution (Figure 7B) and cumulative frequency distribu-
tion (Figure 7C) plots. Similarly, the shift towards lower
Ca2+ spark frequency in cardiac myocytes with Sim-H treat-
ment is shown in Figure 7E, F. There was no observed effect
of Sim-H on Ca2+ spark amplitude, width or duration (data
not shown).
Figure 7
The effects of Sim-H on spontaneous SR Ca2+ release in permeabilised skeletal and cardiac myocytes. (A) Representative linescan confocal
images showing Ca2+ sparks in saponin-permeabilised skeletal FDB ﬁbres after 5 min perfusion with intracellular solution (Control) or
intracellular solution containing 10 μM Sim-H. (B) Frequency distribution histogram for Ca2+ spark frequency in FDB; inset bar graph shows
raw data with median + interquartile range. Ca2+ spark frequency was signiﬁcantly higher (P < 0.05) when analysed using each cell as an
independent sample but was not signiﬁcantly different when each rat was used as the independent sample (Mann–Whitney). (C) Cumulative
frequency distribution for Ca2+ spark frequency in FDB. Data are from 66 control (black/grey) and 78 statin-treated cells (blue) from n = 5
rats. Bin size = 0.2 sparks·100 μm1·s1; tickmarks on X-axis denote bin centre for both groups. (D) Representative linescan confocal images
showing Ca2+ spark parameters in saponin-permeabilised cardiac ventricular myocytes perfused with intracellular solution with or without
10 μM Sim-H for 5 min. (E) Frequency distribution histogram for Ca2+ spark frequency in cardiac myocytes; inset bar graph shows raw data
with median + interquartile range. Ca2+ spark frequency was signiﬁcantly lower (P < 0.05) when analysed using each cell as an independent
sample but was not signiﬁcantly different when each rat was used as the independent sample (Mann–Whitney). (F) Cumulative frequency
distribution for Ca2+ spark frequency in cardiac myocytes. Data are from 100 control (black/grey) and 97 statin-treated cells (red) from
n = 5 rats. Bin size = 0.2 sparks·100 μm1·s1; tickmarks on X-axis denote bin centre for both groups.
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Discussion
Our study demonstrates that simvastatin, a commonly pre-
scribed statin, can directly modulate the gating of skeletal
RyR1 and cardiac RyR2 channels incorporated into planar
phospholipid bilayers. We showed that the mechanisms
controlling simvastatin-induced changes in gating are
different for RyR1 and RyR2 since simvastatin increases
RyR1 Po but can inhibit the opening of RyR2. Simvastatin
increased the Po of RyR1 in a concentration-dependent
fashion. Simvastatin also shifted the distribution of Ca2+
sparks towards higher frequencies in permeabilised skeletal ﬁ-
bres consistent with activation of RyR1 in situ. The ability of
simvastatin to activate RyR1 may be common to other statins
and could explain why cerivastatin, a compound removed
from the market due to reports of rhabdomyolysis, was
shown to trigger Ca2+ release from isolated skeletal SR vesicles
(Inoue et al., 2003).
In our study, activation of RyR1 by Sim-H was rapid and
was completely reversible after wash-out of the drug from
the cytosolic chamber (Figure 1). In contrast, the addition of
Sim-H to the trans (luminal) chamber did not alter RyR1 Po
(Figure 2B), suggesting that the Sim-H binding site resides
on the cytosolic side of RyR1. Lifetime analysis demonstrated
that the primary mechanism driving the Sim-H-induced in-
crease in RyR1 Po at low μM concentrations was the increase
in frequency of channel opening (Figure 3). This is also the
mechanism by which an increase in cytosolic Ca2+ causes
activation of RyR1 (Smith et al., 1986) and RyR2 channels
(Ashley and Williams, 1990; Sitsapesan and Williams, 1990)
suggesting that Sim-H may be sensitizing the RyR1 channels
to cytosolic Ca2+. This mechanism of action is also seen for
other agents such as caffeine (Sitsapesan and Williams,
1990) and adenine nucleotides (Kermode et al., 1998).
Evidence of this mechanism can be seen in Figure 4 where
the activating action of Sim-H is abolished when cytosolic
[Ca2+] is lowered to sub-activating concentrations. Again,
similar to caffeine, when high concentrations of Sim-H are
applied, a cytosolic Ca2+-independent activation can be
initiated. Our results may therefore explain why, in human
permeabilised muscle ﬁbres, application of simvastatin
(10–200 μM) produces a [Ca2+]i transient which is compara-
ble to that of caffeine and inhibited by pretreatment of ﬁbres
with ryanodine (Sirvent et al., 2005b).
It is well documented that leaky RyR1 channels are associ-
ated with skeletal myopathies such as CCD and MH (Chelu
et al., 2006; Guis et al., 2006; Metterlein et al., 2010;
Hedenmalm et al., 2015). In fact, patients susceptible to MH
are reported to be at higher risk of developing muscular side
effects including rhabdomyolysis when taking statin treat-
ment (Metterlein et al., 2010). This is unsurprising given that
we have demonstrated that simvastatin increases cytosolic
Ca2+ sensitivity of RyR1; an effect expected to potentiate
any tendency for an already hyperactive population of
RyR1 channels. In line with this idea, Knoblauch et al.
(2013) reported that mice with the MH mutation, Y524S, ex-
perience an extreme hypermetabolic response to simvastatin
treatment, associated with enhanced SR Ca2+ release from
FDB ﬁbres. The introduction of AICAR, a known RyR1 inhib-
itor, prevented Ca2+ release in both mutant and wild-type
muscle ﬁbres. This is consistent with our ﬁndings that
simvastatin causes SR Ca2+-release by increasing the cyto-
solic Ca2+-sensitivity of RyR1.
We also found that the lactone form, Sim-L, signiﬁ-
cantly increased the Po of RyR1 (Figure 5), a result that is
important for the future design of cholesterol-lowering
agents with reduced muscular side effects. While there are
a variety of structurally distinct statin drugs currently avail-
able, they all possess certain common features. Type 1
statins (e.g. simvastatin, mevastatin) are natural products
or derived from natural products and contain a trans-
decalin-ring motif, while the more recently developed, fully
synthetic, type 2 statins (e.g. atorvastatin, ﬂuvastatin)
contain a pyrrole core (Istvan, 2003). However, common
to all statins is a dihydroxypentanoic acid unit which has
been shown to be the crucial pharmacophore for binding
to HMG-CoA reductase (Istvan and Deisenhofer, 2001). It
is well established that the statin pharmacophore may in-
terconvert between a closed (lactone) form and an open
(hydroxy acid) form. This interconversion occurs readily
in vivo and shows a high level of pH dependence
(Skottheim et al., 2008). Since both Sim-H and Sim-L acti-
vated RyR1 in our hands (Figure 5), it was critical to ensure
that the two forms of simvastatin were not interconverting
during the single-channel experiment. LC-MS conﬁrmed
that the interconversion was too slow to be relevant on
the time-scale of our single-channel experiments. The abil-
ity of both Sim-L and Sim-H to activate RyR1 suggests that
the statin pharmacophore for HMG-CoA reductase is not
crucial for binding to RyR1. Thus, an attractive starting
point for medicinal chemistry would be to design an inhib-
itor of HMG-CoA reductase without an additional ability to
activate RyR1. The number of patients becoming eligible
for statin therapy has increased in recent years; in the UK,
this is as a result of the lowering of the threshold 10 year
cardiovascular risk for statin prescription from 20 to 10%
in 2014 (NICE, 2014). However, the muscle-related side ef-
fects are such that many patients are prescribed a lower
dose of a statin drug than might otherwise be needed to
achieve the desired decrease in LDL cholesterol. In some
cases, patients stop taking statins altogether with implica-
tions for cardiovascular health. The development of a new
class of statin molecules with reduced interaction with
RyR1 may therefore particularly beneﬁt statin users who
are susceptible to myopathy.
Inman, an oral dose of 40mg simvastatin has been shown
to give peak serum levels of up to 10 ng·mL1 (24 nM)
(Ziviani et al., 2001); however, therapeutic regimes of high
dose simvastatin (up to 80 mg·day1) have been shown to
lead to accumulation of simvastatin in tissues at levels in ex-
cess of this (e.g. 12 μM in stomach, 1 μM in spleen and testis)
(Germershausen et al., 1989; Rodrigues, 2010). Thus, the con-
centrations of statins that modulate RyR function in our ex-
periments (≥1 μM) may be similar to those levels that
accumulate inside the cells of patients taking statins. There
are also several well-established drug interactions that arise
because other drugs can further increase statin plasma con-
centration if co-administered. An example of such a drug is
gemfibrozil, which is known to inhibit cytochrome P450,
the enzyme responsible for statin metabolism, thus increas-
ing statin plasma concentrations and increasing the occur-
rence of rhabdomyolysis events (Backman et al., 2000;
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Chang et al., 2004). The closed lactone form of statins is much
more lipophilic than its open form counterparts; in particu-
lar, Sim-L is around three orders of magnitudemore lipophilic
than Sim-H (Serajuddin et al., 1991). The potential for in vivo
interconversion of Sim-H to Sim-L also increases the potential
for increasing concentrations of this lipophilic form to re-
main in muscle tissue, despite apparently lower plasma con-
centrations (Skottheim et al., 2008). The relatively high
lipophilicity of Sim-L would drive its accumulation in tissue
and would promote higher concentrations of statin inside
cells with consequences for RyR channel function. The im-
portance of lipophilicity is supported by the ﬁnding that
the relative severity of statin side effects is not directly related
to efﬁcacy of HMG-CoA reductase inhibition.Rosuvastatin
is the most potent statin in terms of reducing serum LDL cho-
lesterol levels, but muscular related side effects are lower than
with simvastatin (Jones et al., 2003).
A signiﬁcant ﬁnding of this work is that Sim-H lowers the
Po of RyR2 at a concentration (1 μM) that signiﬁcantly
activates RyR1. Higher concentrations then reverse the
inhibition of RyR2 indicating that there may be a high
afﬁnity inactivation site and a lower afﬁnity activation site
on RyR2. The distribution of Ca2+ sparks was also shifted
towards a lower frequency when isolated permeabilised
cardiomyocytes were perfused with Sim-H, consistent with
inhibition of RyR2 in situ.
Thus, the ability of simvastatin to inhibit RyR2 channel
opening could provide protection against those type of ar-
rhythmias arising from SR Ca2+- leak. This is important since
a signiﬁcant proportion of statin users are already
predisposed to Ca2+-dependent arrhythmias and sudden car-
diac death (Ko et al., 2004). In future studies, it will be essen-
tial to investigate if other prescribed statins also inhibit RyR2
while activating RyR1. Our results may explain why previous
reports have suggested that SR Ca2+ homeostasis is altered in
statin-treated skeletal muscle ﬁbres while this is not reported
for cardiac muscle (Sirvent et al., 2005a).
Interestingly, simvastatin was found to reduce fast reen-
trant arrthymias in a rabbit model of experimental atrioven-
tricular nodal reentrant tachycardia (Khori et al., 2015). In
relation to our results, it is conspicuous that statins have pre-
viously been reported to be associated with a decrease in in-
stances of atrial ﬁbrillation (AF) (Siu et al., 2003; Young-Xu
et al., 2003; Amar et al., 2005) and ventricular arrhythmias
in high-risk patients (De Sutter et al., 2000). A recent trial re-
ported that statin therapy signiﬁcantly reduced the
occurance of supraventricular arrhythmias in patients by
29% and prevented recurrence by 33% (Biton et al., 2015). A
systematic review also highlighted the evidence that
preoperative statin therapy can reduce the incidence of
postoperative AF (Kuhn et al., 2014) in patients undergoing
cardiac surgery.
It should be noted that RyR2-independent effects of
statins may also contribute to their ability to protect against
cardiac arrhythmia. For example, statins can alleviate the
arrhythmogenic impact of ischaemia/reperfusion by
restoration of myocardial perfusion through regression of
atheroma (Carnicka et al., 2011; Birnbaum et al., 2015),
increased NO bioavailability and inhibition of platelet
aggregation (Tousoulis et al., 2007). Ischaemia-reperfusion
has also been linked to redox modiﬁcations of RyR2, and it
is possible that interaction with a statin reduces oxidative
damage (Becerra et al., 2016).
The effects of statins have been widely investigated, and it
is likely that a number of mechanisms are responsible for
their differential effects in sketetal and cardiac tissues. In par-
ticular, statins have been shown to limit mitochondrial bio-
genesis and impair mitochondrial function in glycolytic
skeletal muscle while promoting mitochondrial biogenesis
in cardiac muscle (Bouitbir et al., 2012). These effects have
been linked with a marked statin-induced increase in oxida-
tive stress in skeletal muscle compared with the relatively di-
minutive increase in ROS seen in cardiac muscle (Bouitbir
et al., 2012). This, in turn, can be explained by the greater an-
tioxidant capacity of cardiac versus skeletal muscle (Bouitbir
et al., 2012; Bouitbir et al., 2016).
There is no doubt that the inﬂuence of statins on arrhyth-
mia generation may be multifaceted; however, it is tempting
to speculate that inhibition of RyR2 channel opening by simva-
statin is one mechanism capable of confering beneﬁt in those
patients with increased risk of sudden cardiac death by reducing
the opportunity for unregulated diastolic SR Ca2+ leak.
In summary, we demonstrated that simvastatin can act
both as an activator of RyR1 and an inhibitor of RyR2, results
that were observed at the single-channel level and conﬁrmed
by measuring Ca2+-release in permeabilised isolated skeletal
and cardiac cells. We suggest that these effects may underlie
the tendency of simvastatin (and perhaps other statins) to
cause skeletal muscle side effects but could also contribute
to the reported beneﬁcial antiarrhythmic properties of
statins.
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